{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:04:59Z","timestamp":1792253099692,"version":"4.4.0"},"reference-count":22,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2010,6,25]],"date-time":"2010-06-25T00:00:00Z","timestamp":1277424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Angiopoietin\u20102 is expressed in prostate cancer (PCa) bone, liver, and lymph node metastases, whereas, its competitor angiopoietin\u20101 has limited expression in these tissues. Therefore, we hypothesized that the inhibition of angiopoietin\u20102 activity in PCa will impede angiogenesis, tumor growth, and alter bone response in vivo.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>To test our hypothesis we used L1\u201010, a peptide\u2010Fc fusion that inhibits interactions between angiopoietin\u20102 and its receptor tie2. We blocked angiopoietin\u20102 activity using L1\u201010 in established subcutaneous and intra\u2010tibial LuCaP 23.1 xenografts. We then determined the effect of L1\u201010 on survival, tumor growth, serum PSA, proliferation, microvessel density, and angiogenesis\u2010associated gene expression in subcutaneous tumors. We also determined serum PSA, tumor area, and bone response in intra\u2010tibial tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The administration of L1\u201010 decreased tumor volume and serum PSA, and increased survival in SCID mice bearing subcutaneous LuCaP 23.1 tumors. Histomorphometric analysis, showed a further significant decrease in tumor epithelial area within the L1\u201010 treated LuCaP 23.1 subcutaneous tumors (<jats:italic>P<\/jats:italic>\u2009=\u20090.0063). There was also a significant decrease in cell proliferation (<jats:italic>P<\/jats:italic>\u2009=\u20090.012), microvessel density (<jats:italic>P<\/jats:italic>\u2009=\u20090.012), and a significant increase in ANGPT\u20102 and HIF\u20101\u03b1 mRNA expression (<jats:italic>P<\/jats:italic>\u2009\u2264\u20090.05) associated with L1\u201010 treatment. Alternatively, in LuCaP 23.1 intra\u2010tibial tumors L1\u201010 treatment did not significantly change serum PSA, tumor area or bone response.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Our results demonstrate that inhibiting angiopoietin\u20102 activity impedes angiogenesis and growth of LuCaP 23.1 PCa xenografts. Based on these data, we hypothesize that angiopoietin\u20102 inhibition in combination with other therapies may represent a potential therapy for patients with metastatic disease. Prostate 70: 1799\u20131808, 2010. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.21216","type":"journal-article","created":{"date-parts":[[2010,6,25]],"date-time":"2010-06-25T15:01:34Z","timestamp":1277478094000},"page":"1799-1808","source":"Crossref","is-referenced-by-count":24,"title":["Inhibition of angiopoietin\u20102 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability"],"prefix":"10.1002","volume":"70","author":[{"given":"Colm","family":"Morrissey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Dowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore D.","family":"Koreckij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Lakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Fanslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence D.","family":"True","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Vessella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-419X(75)90011-6"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-82-1-96"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/35025215"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.090391"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00491-3"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00167-3"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0045(20000915)45:1<42::AID-PROS5>3.0.CO;2-E"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.06.001"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-007-9116-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07768.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20163"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.175463"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.09.030"},{"key":"e_1_2_6_15_2","first-page":"1039","article-title":"Characterization of a novel androgen\u2010sensitive, prostate\u2010specific antigen\u2010producing prostatic carcinoma xenograft: LuCaP 23","volume":"2","author":"Ellis WJ","year":"1996","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10091"},{"key":"e_1_2_6_17_2","first-page":"23","volume-title":"Bone histomorphometry: Techniques and interpretation","author":"Recker RR","year":"1983"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010901)92:5<1138::AID-CNCR1431>3.0.CO;2-L"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-15"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-008-9209-8"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000087840"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3030"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.136.2.261"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.21216","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.21216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T23:19:55Z","timestamp":1697671195000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.21216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,25]]},"references-count":22,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1002\/pros.21216"],"URL":"https:\/\/doi.org\/10.1002\/pros.21216","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,25]]}}}